Meeting slides
Suggested Readings

Effect of bamlanivimab vs placebo on incidence of COVID-19 among residents and staff of skilled nursing and assisted living facilities: a randomized clinical trial.

Cohen MS, Nirula A, Mulligan MJ, et al. JAMA. 2021;326(1):46-55.

Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial.

Gottlieb RL, Nirula A, Chen P, et al. JAMA. 2021;325(7):632-644.

Early Covid-19 treatment with SARS-CoV-2 neutralizing antibody sotrovimab.

Gupta A, Gonzalez-Rojas Y, Juarez E, et al. medRxiv. 2021. [Epub ahead of print].

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor.

Lan J, Ge J, Yu J, et al. Nature. 2020;581(7807):215-220.

Subcutaneous REGEN-COV antibody combination to prevent Covid-19.

O’Brien MP, Forleo-Neto E, Musser BJ, et al. N Engl J Med. 2021. [Epub ahead of print].

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative Group, Horby PW, Mafham M, Peto L, et al. medRxiv. 2021. [Epub ahead of print].

Racial bias in pulse oximetry measurement.

Sjoding MW, Dickson RP, Iwashyna TJ, Gay SE, Valley TS. N Engl J Med. 2020;383(25):2477-2478.

REGEN-COV antibody cocktail clinical outcomes study in Covid-19 outpatients.

Weinreich DM, Sivapalasingam S, Norton T, et al. medRxiv. 2021. [Epub ahead of print].

Related activities

Clinical Issues in COVID-19

Debates and Discussions About Monoclonal Antibody Therapies

Faculty: Eric S. Daar, MD; Myron J. Levin, MD; Onyema Ogbuagu, MBBCh, FACP, FIDSA
Release: 10/15/2021
Expiration: 10/15/2022